Latest Medical Technology from Bio-Medicine.Org

Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening

Tue, 13 May 2008 09:16:38 MST

PORTLAND, Ore., May 13 /- Dried blood spots are emerging as a breakthrough alternative to expensive serum collection and transport for blood tests. In an article published in the March issue of Journal of Diabetes Science and Technology (2008; 2(2):242-3), Ramakrishnan Lakshmy, PhD, explains that the use of dried blood spots is a "powerful tool", for mass disease screening progr...

XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting

Tue, 13 May 2008 09:16:32 MST

Company Will Host Webcast to Review Data Tuesday, May 13 at 1:00 p.m. EDT (7:00 p.m. CEST) BARCELONA, Spain and MENLO PARK, Calif., May 13 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ) today announced positive six-month follow-up data from the CUSTOM III clinical trial, which assessed the safety and efficacy of the Custom NX(R) drug eluting stent (DES) syst...

Gene Therapy Slows Progression of Fatal Neurodegenerative Disease in Children

Tue, 13 May 2008 08:12:30 MST

NEW ROCHELLE, N.Y., May 13 /- Gene therapy to replace the faulty CLN2 gene, which causes a neurodegenerative disease that is fatal by age 8-12 years, was able to slow significantly the rate of neurologic decline in treated children, according to a paper published online ahead of print in the May 2008 issue (Vol. 19 No. 5) of Human Gene Therapy, a peer-reviewed journal published...

SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents

Tue, 13 May 2008 08:12:21 MST

NATICK, Mass. and BARCELONA, Spain, May 13 /- Boston Scientific Corporation (NYSE: BSX ) today welcomed two-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long-term safety and efficacy of the market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System and reinforce the growing body of positive clinical evidence...

Cardiovascular Researchers Use MEDIHONEY(TM) on Sternal Infections Following Open-Heart Procedures

Tue, 13 May 2008 08:12:09 MST

Full Clinical Study Initiated Following Success with 8 Patients PRINCETON, N.J., May 13 /- Derma Sciences (OTC Bulletin Board: DSCI), a provider of advanced wound care products, today announced that a group of cardiovascular and thoracic surgeons from the University of Wurzburg, Germany, have used MEDIHONEY(TM) dressings to successfully treat 8 patients with deep s...

AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients

Tue, 13 May 2008 07:24:20 MST

-Specific biomarkers for molecular tumor grade and endocrine benefit offer better prediction of individual patient outcome- SAN DIEGO, May 13 /- AviaraDx, Inc. today announced the publication of an article describing the discovery, development and validation of a new molecular biomarker, Aviara MGI(SM) (Molecular Grade Index), that improves the accuracy of breast cance...

XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years

Tue, 13 May 2008 07:24:12 MST

Patients Treated with XIENCE V in SPIRIT III Trial Experience Better Long-Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients Treated with TAXUS BARCELONA, Spain, May 13 /- Long-term data presented for the first time today from the SPIRIT III trial, Abbott's U.S. pivotal trial studying the XIENCE(TM) V Everolimus Eluting C...

FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer

Tue, 13 May 2008 07:24:03 MST

DELAND, Fla., May 13 /- USHIFU, LLC, the clinical trial management provider for Focus Surgery, Inc. (Indianapolis, IN), is pleased to announce conditional written approval pending minor changes to the protocol from the FDA to begin a pivotal trial for the treatment of recurrent prostate cancer with the Sonablate(R) 500 in men who have failed external beam radiation therapy. Dr...

ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354

Tue, 13 May 2008 06:05:05 MST

Drug Represents Potential New Approach for the Treatment of Inflammatory Disease Milestone Triggers $10 Million Payment from Partner GlaxoSmithKline MOUNTAIN VIEW, Calif., May 13 /- ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX354, an orally-available, novel small molecule compound designed to specifically t...

NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.

Tue, 13 May 2008 05:08:00 MST

SOPHIA ANTIPOLIS, France, May 13 /- NicOx S.A. (Eurolist: COX) today announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies' collaborative agreement to develop new nitric oxide-donating antihypertensive agents using NicOx' proprietary technology. Three drug candida...

Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows

Tue, 13 May 2008 05:07:53 MST

LOS ANGELES, May 13 /- New soluble polymer material designed to stop bone bleeding in surgery improves bone fusion and healing, according to a new animal study just published in the Annals of Thoracic Surgery (ATS). The findings come on the heels of recently published research showing that the use of the new polymer may lower the risk of surgical infections. Researchers from t...

Napo Presents at ISPOR Meeting in Toronto

Mon, 12 May 2008 07:07:59 MST

SOUTH SAN FRANCISCO, Calif., May 12 /- Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU), announces that it presented a poster in collaboration with QualityMetric, Inc. describing the development of a patient reported outcomes questionnaire focused on the Health-Related Quality of Life (HR-QoL) aspects of chronic diarrhea in persons living with HIV/AIDS at the 13th Inte...

Cardinal Health Completes Enturia Acquisition

Mon, 12 May 2008 07:07:52 MST

ChloraPrep(R) Products Expand Infection Prevention Business DUBLIN, Ohio, May 12 /- Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, today announced it has completed the acquisition of assets of privately held Enturia, Inc., the manufacturer of infection prevention products sold under the ChloraP...

Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation

Mon, 12 May 2008 06:34:30 MST

- Intercell AG ('Intercell') to acquire Iomai Corporation ('Iomai') in a fully recommended share/cash transaction for USD 6.60 per share of Iomai's common stock representing a fully diluted equity value of Iomai of approximately USD 189 million (EUR 122 million). Acquisition to be accomplished through stock-for-stock exchange for approximately 41 percent of Iomai's current shares outsta...

Prism Glasses Expand the View for Patients with Hemianopia

Mon, 12 May 2008 01:20:44 MST

Schepens study opens way for high-power permanent version of the glasses and larger new study BOSTON, May 12 /- Innovative prism glasses can significantly improve the vision and the daily lives of patients with hemianopia, a condition that blinds half the visual field in both eyes. The peripheral prism glasses, which were invented by Dr. Eli Peli, a Seni...

Lupus Under the Spotlight: U.S. Congress Shows Support for Women's Health Issues

Mon, 12 May 2008 10:09:06 MST

NEW YORK, May 12 /PRNewswire-USNewswire/ -- The Alliance for Lupus Research (ALR) commends the Senate on its passage of a resolution supporting the goals and ideals of National Women's Health Week that begins annually on Mother's Day. The resolution, introduced by Senators Russ Feingold (D-WI) and Olympia Snowe (R-ME) calls on all Americans to take the week of May 11th - May 17th as an oppor...

GeoVax Secures $10 Million Financing Commitment

Mon, 12 May 2008 08:56:21 MST

ATLANTA, May 12 /- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta- based HIV/AIDS vaccine development company, announced today that it has entered into a $10 million common stock purchase agreement with Fusion Capital Fund II, LLC, a Chicago-based institutional investor. The Company may sell up to $10 million of its common stock to Fusion Capital from time...

St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity

Mon, 12 May 2008 08:56:10 MST

Immune cells adjust their function like a radio dial, not an on/off light switch; a discovery that hints at how autoimmune disease may develop late in life MEMPHIS, Tenn., May 12 /PRNewswire-USNewswire/ -- A St. Jude Children's Research Hospital study shows that T cells, the body's master immune regulators, do not use simple on/off switches to govern the cellular machinery that regulates...

Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy

Mon, 12 May 2008 08:56:01 MST

ANN ARBOR, Mich., May 12 /- Velcura Therapeutics, Inc. announced the successful completion of a first-in-man clinical trial for its lead compound, VEL-0230, which the company is investigating as a treatment for Rheumatoid Arthritis (RA) and other bone diseases. In extensive preclinical studies, VEL-0230 proved to be a powerful anti-inflammatory agent that also stimulates bone fo...

Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury

Mon, 12 May 2008 08:55:54 MST

Results show promising neurological recovery in severely-injured, acute cervical spinal cord injury patients treated with Cethrin HOPKINTON, Mass., May 12 /- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE ) today announced 12-month interim data from its Phase I/IIa clinical trial of Cethrin, a proprietary recombinant protein that is being investigated for its poten...